The predictive value of cytotoxic crossmatch analysis before allo-SCT remains unclear. We retrospectively analyzed the clinical impact of cytotoxic T-and B-cell crossmatch testing before allo-SCT between January 2000 and June 2005. Cytotoxic crossmatches were performed in 157 patients receiving stem cells from matched unrelated donors or an HLA-A, -B or -DRB1 allele mismatched graft. Ninety patients are still alive. Eleven patients rejected their grafts. One of 11 patients with rejection was positive in a T-cell crossmatch before allo-SCT and 4 of 11 in B-cell crossmatches. T-cell crossmatches showed a sensitivity of 9% and a specificity of 97% compared with 36 and 86% for B-cell crossmatches. Positive T-and/or B-crossmatch before SCT had no predictive value for survival in this study as compared with patients with a negative crossmatch. In conclusion, the pretransplant cytotoxic T-and/or B-crossmatch is a poor predictor of rejection after allo-SCT.
Introduction
After organ transplantation, it is well known that a substantial number of both early and late graft rejection may be caused by the presence of alloantibodies. 1, 2 Crossmatch techniques have been introduced to detect antidonor antibodies before organ transplantation and thereby to avoid graft rejections. 3, 4 Alloantibodies after organ transplantation may be directed against both HLA and non-HLA Ags. 5 The first crossmatch techniques to be introduced used C 0 -dependent cytotoxicity with donor T-and/or B-lymphocytes as target cells allowing detection of donor-reactive HLA class I-and II-specific antibodies. 3 By applying flow cytometry to the crossmatch tests, increased sensitivity with regard to detection of donor-reactive antibodies has been accomplished. 5 Also, for the assessment of panel-reactive antibodies, more sensitive solid phase techniques using single HLA Ags in ELISA, flow cytometry or the Luminex formats have been introduced.
The importance of Ab-mediated rejection of allogeneic stem cell grafts is more controversial. Previous studies in a large animal model showed successful marrow engraftment in the presence of circulating cytotoxic Abs against donor cells, a finding that indicates that cellular rather than humoral mechanisms underlie graft rejection in sensitized recipients. 6 However, recent data from mouse models indicate that the presence of preformed donor-reactive Abs is a dominant barrier for BM engraftment in allosensitized recipients. 7, 8 In contrast to organ transplantation, data on the clinical outcome after allo-SCT across a positive crossmatch are scarce. Previous work by Anasetti et al. 9 showed that patients with a positive crossmatch had a significantly increased risk of rejection compared with patients with a negative crossmatch. Ottinger et al.
10 also showed that a positive crossmatch may be correlated to an increased risk for rejection after allo-SCT. However, in both these studies, patients with a positive crossmatch and increased risk for rejection received a major HLA-Ag mismatched graft. In this study, we wanted to evaluate the clinical importance of performing T-and B-cell cytotoxic crossmatches before allo-SCT with matched unrelated donors (MUD) or HLA-A, -B or -DRB1 allele mismatched unrelated donors by retrospectively analyzing crossmatches performed before allo-SCT. Although Abs may be involved in rejection after allo-SCT, the question is whether cytotoxic crossmatch testing before MUD allo-SCT is really assessing the relevant target Ags.
Materials and methods

Patients
We retrospectively analyzed the results of the cytotoxic T-and/or B-cell crossmatching performed before allo-SCT at Karolinska University Hospital between January 2000 and June 2005. During this period, we performed 230 MUD allo-SCTs, and cytotoxic crossmatch tests were performed before 157 of these transplants. Only patients receiving grafts from unrelated donors were crossmatch tested. Of the patients receiving myeloablative pretreatment, conditioning was either with CY at 60 mg/kg on two consecutive days (À5 and À4 or À4 and À3) combined with fractionated TBI 3 Gy for 4 consecutive days or a combination of BU (4 mg/kg/day Â 4) and CY at 60 mg/kg on two consecutive days. 11 Seventy patients received reduced intensity conditioning as preparative treatment before allo-SCT as described earlier. 12 All patients with HLA-A, -B and -DRB1 MUD received 4-5 days of (days À5 or À4 to À1) treatment with antithymocyte globulin at a total dose of 4-8 mg/kg. 13 All patients and donors were typed using PCR-SSP high resolution typing for both HLA class I and II (HLA-A, -B, -C, -DRB1 and -DQ) Ags.
14 A MUD graft for HLA-A, -B and DRB1 was given to 130 patients and 27 patients received an HLA-A, -B or DRB1 allele mismatched graft. Most patients received CYA combined with a short course of MTX as GVHD prophylaxis. 15 The other immunosuppressive protocols, such as tacrolimus and sirolimus or CYA and mycophenolate mofetil, have been described elsewhere. 12 Definition of rejection after allo-SCT has been described earlier. 16 For detailed patient and donor characterization, see Table 1 . Supportive care has been published in detail earlier. 17 Cytotoxic crossmatches T-and B-cell crossmatches were performed according to the standard C 0 -dependent method described earlier. 4, 18 Briefly, after Ficoll density gradient centrifugation of a peripheral blood sample, donor T and B cells were isolated using Ab-coated paramagnetic beads-anti-CD 8 coated beads for T cells and anti-HLA class II-coated beads for HLA-class II expressing cells (Dynal, Oslo, Norway). They were incubated with the recipient serum and rabbit C 0 . Presence or absence of C 0 -fixing antidonor Abs in the patient's serum was evaluated using a fluorescent dye (acridineorange/ethidiumbromide). A crossmatch is considered positive if more than 10% of the target cells are killed in excess of the number of dead cells incubated in a negative control serum.
Statistics
The probability of OS was estimated using the KaplanMeier product-limit method and compared with the logrank test. 19 In the uni-and multivariate risk-factor analysis for graft failure, the logistic regression model was used. Only factors at the 10% level from the univariate analysis were assessed in the multivariate (stepwise) analysis.
Results
Patients
During the study period, 157 patients receiving allo-SCT from MUD or an allele mismatched donor were analyzed with cytotoxic crossmatch. Of these, 11 patients (7%) rejected the graft according to chimerism analysis. Of those rejecting the graft, nine patients received reduced intensity conditioning as pretreatment and two patients received an allele mismatched graft. Seven of the 11 patients rejecting their graft died (64%).
Cytotoxic T-and/or B-cell crossmatch Of the 157 patients evaluated with cytotoxic crossmatch before allo-SCT, 148 and 139 patients were tested with T-and B-cell crossmatching, respectively. Of the 148 patients tested with cytotoxic T-cell crossmatch, four patients received allo-SCT across a positive crossmatch out of which one rejected the graft. Twenty-two of 139 (16%) had a positive B-cell crossmatch before allo-SCT, but only four of these patients (18%) rejected their graft. Sensitivity was 9% in T-cell crossmatches and 36% in B-cell crossmatches. Specificity was 97 and 86% for T-and B-cell crossmatches, respectively. In multivariate analysis, significant risk factors for rejection in this patient group were donor age, immunosuppressive therapy other than CYA þ MTX and a positive B-cell crossmatch (Table 2) . However, a positive T-and/or B-cell crossmatch before allo-SCT did not predict survival in allo-SCT patients. Mismatch in HLA-C was not correlated to rejection in multivariate analysis.
Discussion
In organ transplantation, there has been an increasing interest in Ab-mediated graft failure and the importance of alloantibodies against HLA and non-HLA targets is increasingly recognized as critical for both acute and chronic graft failure. 5, 20 A positive crossmatch before kidney transplantation has been associated with rejection and a poor outcome. 3 Graft rejections after allogeneic hematopoietic SCT have occurred as a relatively rare complication when using myeloablative conditioning. 21 However, when the standard treatment of the graft or host is modified, such as reduced intensity conditioning pretreatment, rejections emerge as a more common problem. Mechanisms of graft rejection have not been fully understood but are primarily considered as cellular mediated immune responses including not only T-cell-and natural killer cell responses but also involvement of different cytokines and FasL-mediated functions. 22 The risk of graft failure increases with the degree of genetic disparity between donor and recipient as well as depending on whether immune competent cells remain present in the recipient after conditioning.
Although Ab-mediated rejection after allo-SCT is controversial, recent data in animal models indicate that preformed donor-reactive Abs are a dominant barrier for BM engraftment in allosensitized recipients. 7, 8 In patients receiving major HLA-Ag mismatched allo-SCT, a positive crossmatch has been significantly correlated to increased risk for graft failure and inferior survival as compared with patients transplanted against a negative crossmatch. 9, 10 Taken together, on the basis of the above-mentioned publications, we have on a regular basis performed cytotoxic crossmatches in allo-SCT patients before transplantation since 2000. As cytotoxic crossmatch testing against T-and B cells involves donor-specific Abs mainly directed against HLA Ags, the question arises whether this test is relevant when using an HLA matched or allele mismatched donor. The predictive value of the performed cytotoxic crossmatches was therefore retrospectively evaluated.
In this study, most donors were MUD and a minority received an allele mismatched donor. No patient received a major HLA-Ag mismatched donor. Patients with donors older than 45 years fared worse according to multivariate analysis. This is in agreement with earlier studies indicating a delayed immune recovery in patients receiving allo-SCT from older donors. 23 In multivariate analysis also, a positive B-cell crossmatch was significantly correlated to graft failure but only four of 22 patients with a positive crossmatch rejected the graft. Patients transplanted with a positive crossmatch did not show any inferior survival as compared with patients with a negative crossmatch. The reason why B-cell crossmatch was significantly correlated to graft failure according to multivariate analysis but no difference was seen in OS is probably because some patients may survive graft rejection. In this study, 4 of 11 survived after graft rejection. Another reason is probably the small numbers of patients with a positive B-cell crossmatch found in this study, which may have an impact on multivariate analysis. However, if a patient is positive in B-cell crossmatch before allo-SCT, we recommend that the patient is also analyzed with solid phase methods to detect anti-HLA Abs. Although specificity was high in crossmatches, the sensitivity was very low indicating that this technique is a poor predictor of rejection after allo-SCT and therefore may prove unsuitable in patients undergoing allogeneic hematopoietic SCT with well-matched donors. However, as data on preformed anti-HLA Abs were not available in this study, one should not exclude the possibility of using crossmatches in patients who have been sensitized to HLA before transplantation by, for instance, plt transfusions or in patients before cord blood transplantation. Moreover, it would be of interest to introduce new techniques capable of defining patients at risk of rejection after allo-SCT.
For instance, the introduction of more sensitive and specific solid phase methods to detect anti-HLA Abs may be used for patients receiving an HLA-mismatched graft. 24 This may be of particular use in patients receiving cord blood transplants or haploidentical allo-SCT. 25 The role of anti-HLA Abs in MUD or allele mismatched donors, remains to be elucidated. To investigate the importance of screening for anti-HLA Abs using solid phase methods, a prospective study comparing cytotoxic crossmatches and the presence of panel-reactive Abs should be performed.
Moreover, in a recent study, we have shown that recipient Abs toward donor CD34 þ /VEGFR-2 þ cells are correlated to rejection. 16 Significantly higher numbers of patients with rejections had Abs against donor CD34 þ / VEGFR-2 þ cells compared with patients without rejections. We believe that these cells may prove to be a more suitable target for crossmatches as compared with lymphocytes before allo-SCT and will evaluate this further in a prospective study.
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